Published On: 5/8/2025
EASL 2025 Research: Presentation by Michael Roden, MD
Target RWE’s MASH steering committee member Michael Roden, MD co-authored a new Target RWE study which was presented at EASL 2025 titled, “Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real-world setting.”
In this new analysis from the TARGET-NASH cohort, researchers demonstrate that individuals with type 2 diabetes face significantly higher risk of progressing from MASH to cirrhosis, independent of age, sex, or fibrosis risk group.
This data underscores the urgent need for early MASH detection in people with T2D, especially as MASLD continues to rise globally. Watch the video presentation to learn more about the impact of diabetes on liver disease progression and why proactive screening and intervention strategies are critical to reducing the burden of MASLD-related cirrhosis in at-risk populations.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
05/08/2025
EASL 2025 Research: Presentation by Michael Roden, MD -
04/25/2025
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis? -
04/03/2025
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data -
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life -
03/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry)